Floatz logo

Carfilzomib

Plasmacytosis

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Plasmacytosis cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
University of Colorado, Denver
Phase 1/2CCC
Bortezomib
University of Colorado, Denver
Phase 1/2CCC
Evomela
University of Colorado, Denver
Phase 1/2CCC
Inno-206
University of Colorado, Denver
Phase 1/2CCC
PREDNISONE TABLETS
University of Colorado, Denver
Phase 1/2CCC
FILGRASTIM
University of Colorado, Denver
Phase 1/2CCC
Cyclophosphamide
University of Colorado, Denver
Phase 1/2CCC
Panobinostat
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
MRDDormant
BB
Indicative ·
64 / 100
View asset →
Stage III Adult Diffuse Large Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →